{"success":true,"data":{"pressRelease":{"id":"160048","rtpr_id":"nPn21xWHja-20261005","ticker":"SPRY","exchange":"NASDAQ","all_tickers":["SPRY"],"title":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY","author":"PR Newswire","published_at":"2026-10-05T07:28:00.035Z","article_body":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY\nPR Newswire\n\nNEW YORK, Oct. 5, 2026\n\nNEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789272-1&h=2481050129&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group)\n reminds investors of a class action lawsuit against ARS Pharmaceuticals,\nInc. (\"ARS\" or \"the Company\") (NASDAQ: SPRY\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789272-1&h=1052182442&u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FSPRY&a=SPRY)\n) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and\nRule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of SPRY during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: March 9, 2026 to June 24, 2026\n\nDEADLINE: October 5, 2026\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. ARS knew its timeline for CVS Caremark\nformulary and coverage approval decisions for neffy faced issues. The\nCompany's commercialization plans would be impacted by this delay. Based on\nthese facts, ARS's public statements were false and materially misleading\nthroughout the class period.\n\nIf you are a shareholder who suffered a loss, contact us to participate\n(mailto:David@djslawllp.com) .\n\nWHY DJS LAW GROUP? DJS Law Group's David Schwartz is a founding partner of\nSchall Brown & Schwartz LLP, and his primary focus is to enhance investor\nreturn through balanced counseling and aggressive advocacy. We specialize in\nsecurities class actions, corporate governance litigation, and\ndomestic/international M&A appraisals. Our clients are some of the largest\nand most sophisticated hedge funds and alternative asset managers in the\nworld. The litigation claims of our clients are extraordinarily valuable\nassets that demand respect, focus, and results.\n\nJoin the case (mailto:David@djslawllp.com)  to recover your losses.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\nCONTACT:\n\nDavid J. Schwartz\n\nDJS Law Group\n\n274 White Plains Road, Suite 1\n\nEastchester, NY 10709\n\nPhone: 914-206-9742\n\nEmail: David@djslawllp.com (mailto:David@djslawllp.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/ars-pharmaceuticals-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--spry-302897926.html\n(https://www.prnewswire.com/news-releases/ars-pharmaceuticals-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--spry-302897926.html)\n\nSOURCE DJS Law Group LLP\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn21xWHja-20261005","title":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY","author":"PR Newswire","ticker":"SPRY","created":"2026-10-05T07:28:00.035Z","tickers":["SPRY"],"exchange":"NASDAQ","article_body":"ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY\nPR Newswire\n\nNEW YORK, Oct. 5, 2026\n\nNEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789272-1&h=2481050129&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group)\n reminds investors of a class action lawsuit against ARS Pharmaceuticals,\nInc. (\"ARS\" or \"the Company\") (NASDAQ: SPRY\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789272-1&h=1052182442&u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FSPRY&a=SPRY)\n) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and\nRule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of SPRY during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: March 9, 2026 to June 24, 2026\n\nDEADLINE: October 5, 2026\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. ARS knew its timeline for CVS Caremark\nformulary and coverage approval decisions for neffy faced issues. The\nCompany's commercialization plans would be impacted by this delay. Based on\nthese facts, ARS's public statements were false and materially misleading\nthroughout the class period.\n\nIf you are a shareholder who suffered a loss, contact us to participate\n(mailto:David@djslawllp.com) .\n\nWHY DJS LAW GROUP? DJS Law Group's David Schwartz is a founding partner of\nSchall Brown & Schwartz LLP, and his primary focus is to enhance investor\nreturn through balanced counseling and aggressive advocacy. We specialize in\nsecurities class actions, corporate governance litigation, and\ndomestic/international M&A appraisals. Our clients are some of the largest\nand most sophisticated hedge funds and alternative asset managers in the\nworld. The litigation claims of our clients are extraordinarily valuable\nassets that demand respect, focus, and results.\n\nJoin the case (mailto:David@djslawllp.com)  to recover your losses.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\nCONTACT:\n\nDavid J. Schwartz\n\nDJS Law Group\n\n274 White Plains Road, Suite 1\n\nEastchester, NY 10709\n\nPhone: 914-206-9742\n\nEmail: David@djslawllp.com (mailto:David@djslawllp.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/ars-pharmaceuticals-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--spry-302897926.html\n(https://www.prnewswire.com/news-releases/ars-pharmaceuticals-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--spry-302897926.html)\n\nSOURCE DJS Law Group LLP\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-05T07:28:00.11479754Z","server_sent_at_ms":1791185280114},"received_at":"2026-10-05T07:28:00.166Z","source_url":"https://www.prnewswire.com/news-releases/ars-pharmaceuticals-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--spry-302897926.html"},"analysis":{"id":"148625","press_release_id":"160048","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["alleged misleading statements regarding CVS Caremark formulary/coverage timeline for neffy","commercialization plans reportedly impacted by payer approval delays"],"eventType":"legal_litigation","narrative":"The DJS Law Group issued a shareholder-solicitation notice reminding SPRY investors of a securities class action alleging false and misleading statements about the timeline for CVS Caremark formulary decisions for neffy.\n\nThe proposed class period runs from March 9, 2026 to June 24, 2026, with a lead-plaintiff deadline of October 5, 2026.\n\nThis is law-firm marketing rather than an issuer disclosure or court action; treat as low-signal noise, though the underlying claims echo commercialization-delay risk around neffy.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; monitor issuer for direct disclosure on CVS Caremark coverage timeline."},"keyFigures":{"customDimensions":{"class_period":"March 9, 2026 to June 24, 2026","lead_plaintiff_deadline":"October 5, 2026"}},"namedEntities":{"people":[{"name":"David J. Schwartz","role":"founding partner, DJS Law Group"}],"products":["neffy"],"companies":[{"name":"DJS Law Group","relationship":"plaintiff law firm"},{"name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","relationship":"defendant/named issuer"},{"name":"CVS Caremark","relationship":"mentioned in allegations (formulary decision-maker)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by DJS Law Group reminding investors of a class action and lead-plaintiff deadline. No issuer disclosure, no certified class, and no settlement announced."},"tickerRelevance":{"others":[],"primary":"SPRY"},"globalImportance":12,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"The DJS Law Group issued a shareholder-solicitation notice reminding SPRY investors of a securities class action alleging false and misleading statements about the timeline for CVS Caremark formulary decisions for neffy.\n\nThe proposed class period runs from March 9, 2026 to June 24, 2026, with a lead-plaintiff deadline of October 5, 2026.\n\nThis is law-firm marketing rather than an issuer disclosure or court action; treat as low-signal noise, though the underlying claims echo commercialization-delay risk around neffy.","key_figures":{"customDimensions":{"class_period":"March 9, 2026 to June 24, 2026","lead_plaintiff_deadline":"October 5, 2026"}},"named_entities":{"people":[{"name":"David J. Schwartz","role":"founding partner, DJS Law Group"}],"products":["neffy"],"companies":[{"name":"DJS Law Group","relationship":"plaintiff law firm"},{"name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","relationship":"defendant/named issuer"},{"name":"CVS Caremark","relationship":"mentioned in allegations (formulary decision-maker)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T07:28:04.776Z","global_importance":12,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4599,"modelName":"glm-5.3-flashx"}}